Narcolepsy Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the narcolepsy therapeutics market size is expected to grow from USD 4.11 billion in 2025 to USD 4.42 billion in 2026 and is forecast to reach USD 6.36 billion by 2031 at 7.56% CAGR over 2026-2031.

This report Segments the Industry Into by Type (Narcolepsy Type 1, Narcolepsy Type 2, and Secondary Narcolepsy), Product Class (CNS Stimulants, Sodium Oxybate, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Narcolepsy Therapeutics Market Trends and Insights

FDA/EMA Approvals of Novel Agents

New approvals validate orexin biology beyond stimulants. Lumryz gained clearance as the first once-nightly extended-release sodium oxybate and demonstrated efficacy in the REST-ON Phase 3 trial. Pediatric approvals broaden reach, with extended-release sodium oxybate now indicated from age 7 years. TAK-861 showed significant improvements in sleep latency and cataplexy in Phase 2b trials, encouraging a Phase 3 global programme. Orphan-drug exclusivity offers seven-year protection and fuels R&D pipelines. EMA alignment reduces duplicate testing and accelerates European launches for sodium oxybate and histamine H3 antagonists.

Increasing Clinical Trials for Narcolepsy Therapeutics

Industry confidence rises as trials pursue disease-modifying goals rather than symptom control. AXS-12 met SYMPHONY Phase 3 endpoints with an 83% cataplexy reduction, prompting NDA preparation. Alkermes' ALKS-2680 improved sleep latency by up to 34 minutes in early studies. Harmony Biosciences acquired HBS-102, expanding into MCHR1 antagonism to tackle REM dysregulation. Beacon Biosignals partners with Takeda to apply neuro-biomarkers that sharpen endpoints and may cut trial time. Investment in CNS imaging rises, evidenced by Clario's NeuroRx acquisition that brings fMRI capacity to late-stage programmes.

High Therapy Cost and Orphan-Drug Pricing

Lumryz carries an annual US list price of USD 177,034, which, while competitive with legacy oxybate, remains many times higher than stimulants and poses affordability challenges. Xyrem rose from USD 11,169 in 2007 to USD 182,804, triggering investigation into anti-competitive tactics. Payers note that 51% of 2023 drug approvals were orphan, adding urgency to align prices with measurable benefit. Emerging markets find US-centric pricing untenable, delaying launches or limiting reimbursement scope. Outcomes-based contracts start to appear, linking payment to improved Epworth Sleepiness Scale scores and reduced cataplexy episodes.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Support and Reimbursement Expansion
2. Growing Focus on Personalised and Combination-Therapy Protocols
3. Adverse-Event Profile and Abuse Potential of Sodium Oxybate

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The Narcolepsy therapeutics market size for Type 1 remained dominant in 2025 as 60.92% of total therapy spending, driven by cataplexy-targeted sodium oxybate prescriptions. Type 2 is growing fastest at an 10.79% CAGR, supported by refined multiple sleep latency testing that differentiates it from idiopathic hypersomnia. Cerebrospinal fluid analysis via HPLC now discerns inactive hypocretin fragments, cutting misclassification risk and boosting accurate therapy alignment. Clinicians often reserve oxybate for Type 1 while favouring stimulants or histamine H3 antagonists for Type 2, creating separate pricing ladders and payer policies. Secondary narcolepsy from structural brain injuries forms a niche but clinically significant slice that draws attention to rehabilitation protocols and neuro-imaging referral pathways.

Improved diagnostic throughput also widens the Narcolepsy therapeutics market, with community neurologists adopting simplified scoring that flags abnormal REM transitions. Academic centres pilot tele-polysomnography which reduces waitlists and facilitates earlier start of disease-modifying trials. Type 2 patient-reported outcomes show faster work productivity gains once correctly classified, strengthening the economic rationale for payers to fund confirmatory CSF testing. Awareness campaigns run by patient groups increase research registries, offering real-world evidence that supports label expansion for novel agents. Regional variance persists, though, with Asia-Pacific under-diagnosing Type 2 due to limited MSLT capacity, signalling opportunity for portable diagnostic devices.

Complete Report Scope:

• By Type
  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Secondary Narcolepsy
• By Product Class
  • CNS Stimulants
  • Sodium Oxybate
  • Histamine H3 Antagonists
  • Dopamine
  • Antidepressants
  • OX2R Agonists
  • Other Therapies
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 42.05% of the Narcolepsy therapeutics market in 2025 on the back of favourable reimbursement, specialist density, and early uptake of once-nightly oxybate. Payer formularies prioritise value-based contracts that hinge on Epworth Sleepiness Scale reduction, a policy that encourages rapid cycling toward clinically superior regimens. Digital health regulations allow continuous remote monitoring, facilitating adherence tracking by sleep centres and plugging gaps between urban and rural care.

Europe contributes steady growth as orphan-drug incentives and EMA centralised procedures shorten time from approval to reimbursement. Co-payment caps in Western Europe sustain broad access, while Central and Eastern Europe gradually close reimbursement gaps through HTA reforms that benchmark outcomes data from larger markets. EU cross-border healthcare rules have spurred patient travel for complex sleep studies, indirectly boosting diagnostic throughput.

Asia-Pacific is the fastest expanding region at a 11.87% CAGR, thanks to rising diagnosis rates, regulatory reforms, and urban hospital investment. China's recent endorsement of lemborexant for insomnia signals growing acceptance of sleep therapeutics and sets a regulatory precedent for orexin agents. Japan reports USD 2,531 annual healthcare spend per narcolepsy patient versus USD 266 for controls, illuminating the economic benefit of effective therapy. Australia widens coverage under the Pharmaceutical Benefits Scheme, and India's private insurers experiment with bundled tele-sleep packages. Middle East, Africa, and Latin America still struggle with reimbursement asymmetry and neurologist shortages, yet pilot telemedicine projects funded by development banks hint at latent demand once cost barriers ease.

1. Jazz Pharmaceuticals plc
2. Harmony Biosciences
3. Avadel Pharmaceuticals
4. Takeda Pharmaceuticals
5. Teva Pharmaceutical Industries
6. Axsome Therapeutics
7. Alkermes plc
8. Zevra Therapeutics
9. Amneal Pharmaceuticals
10. Azurity Pharmaceuticals Inc.
11. Novartis
12. Hikma Pharmaceuticals
13. Arena Pharmaceuticals
14. Prasco LLC
15. Sunovion Pharmaceuticals
16. Johnson & Johnson
17. Lundbeck A/S
18. Lupin
19. Torrent Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support